NCT04967443View on ClinicalTrials.gov

Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 22, 2021

Primary Completion Date

February 15, 2022

Study Completion Date

February 15, 2022

Conditions
HypertensionHeart Failure
Interventions
DRUG

Prazosin HCl 2mg

Prazosin HCL 1 X 2 mg capsule.

DRUG

Prazosin HCl 1 mg

Prazosin HCl 2 X 1 mg capsule.

DRUG

Prazosin HCl 5 mg

Prazosin HCL 1 X 5 mg capsule.

Trial Locations (1)

78229

Clinical Trials of Texas, LLC, San Antonio

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04967443 - Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules | Biotech Hunter | Biotech Hunter